Anti-double-stranded DNA B-cell receptor (Anti-dsDNA BCR)

Anti-double-stranded DNA B-cell receptors (anti-dsDNA BCRs) are specialized surface immunoglobulins found on autoreactive B cells that specifically recognize and bind to double-stranded DNA (dsDNA). Under normal physiological conditions, these B cells are typically eliminated or rendered anergic through immune tolerance mechanisms to prevent the development of autoimmunity (Source: PubMed, PMID: 30241744). However, in patients with Systemic Lupus Erythematosus (SLE), these cells escape tolerance, proliferate, and differentiate into plasma cells that secrete high-affinity anti-dsDNA autoantibodies (Source: Nature Reviews Rheumatology, 2020). These antibodies contribute to the formation of immune complexes that deposit in tissues, particularly the kidneys, leading to lupus nephritis and systemic inflammation (Source: StatPearls, 2023). Therapeutic strategies targeting anti-dsDNA BCRs aim to selectively deplete these pathogenic B-cell clones while sparing the rest of the healthy B-cell repertoire. Emerging approaches include Chimeric Autoantibody Receptor (CAAR) T-cell therapy, which uses the dsDNA antigen to direct T cells to kill only the B cells expressing the specific anti-dsDNA receptor (Source: Science, 2016; Journal of Clinical Investigation, 2023).

Other names

Anti-dsDNA B-cell receptordsDNA-specific B-cell receptorDNA-reactive B-cell receptorAnti-DNA B-cell receptordsDNA-binding B-cell receptor

Selective depletion of autoreactive B-cell clones expressing the anti-dsDNA receptor, inhibition of B-cell receptor signaling, and reduction of pathogenic autoantibody production.